跳至主要内容
临床试验/NCT00626262
NCT00626262已完成4 期

An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

AstraZeneca0 个研究点目标入组 60 人开始时间: 2002年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
60
主要终点
To compare the maximum acid output during pentagastrin stimulation after 10 days of Nexium dosing administered orally with 10 days dosing via intravenous administration.

研究概览

简要总结

The purpose of this study is to examine the effects of Nexium at a dose of 20mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Heartburn on 2 out of the last 7 days prior to screening or a diagnosis of GERD (with or without a diagnosis of Erosive eosphagitis) or a documented diagnosis of GERD within 6 months prior to screening, with or without a history of EE.
  • Body Mass Index within the limits specified in the protocol.

排除标准

  • History of esophageal, duodenal or gastric surgery
  • History of severe liver disease.
  • Any other significant disease or pathology judged to be clinically significant by the investigator.

研究组 & 干预措施

1

Experimental

20mg oral

干预措施: Esomeprazole (Drug)

2

Experimental

20mg IV

干预措施: Esomeprazole (Drug)

结局指标

主要结局

To compare the maximum acid output during pentagastrin stimulation after 10 days of Nexium dosing administered orally with 10 days dosing via intravenous administration.

时间窗: Every 10 days

次要结局

  • To compare basal acid output at steady state and when switching between Oral and IV administration of Nexium.(Post Day 10)
  • To compare maximum acid output when switching between Oral and IV adminstration of Nexium(Post Day 10)
  • Safety assessment via adverse event recording.(At each visit)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验

Open, Randomized, Two Way Crossover Study Comparing... | 临床试验